Roche has been trumpeting the rapid uptake of its new eye disease drug Vabysmo as it takes on Regeneron and Bayer's mighty Eylea in the US – and could soon start making inroads against its
Cancer Research UK has expanded an alliance with investment group Deep Science Ventures with a commitment to support the formation up to 10 new oncology startups.
While immunotherapies have transformed treatment of many types of cancer, they do sometimes fail to have an impact – as Merck & Co has just observed in a study of Keytruda in
It has suspected for many years that some diseases may be linked to non-coding or 'junk' DNA, but the mechanism behind the pathology hasn't been worked out.
AstraZeneca and Merck's PARP inhibitor Lynparza has carved out blockbuster revenues across uses in breast, ovarian, prostate and pancreatic cancer, but colorectal cancer won’t be added to t
China's Simcere Pharmaceutical has been granted approval in its home market for Cosela, a drug designed to limit the side effects of cancer chemotherapy, partnered with US biotech G1 Therap